What Gilead's Quarter ended Sep 30, 2026 10-Q says: 6 signals
Gilead filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses acquisition announced, acquisition completed and bookings decline.
Public (GILD)Biotechnology Research10,000+ employeesgilead.comLinkedIn
Get Gilead's live signals in Claude or ChatGPT, or by API
What changed at Gilead this week? Use Autobound signals for gilead.com.- Filed
- Oct 29, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 16
Source: Autobound Signal API · 74 signals tracked for Gilead · updated
10-Q · latest 10
What Gilead's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 6 signals
Gilead completed acquisitions of Arcellx for $7.0B, Tubulis for $3.1B, and Ouro Medicines
During the nine months ended September 30, 2026, Gilead completed the acquisitions of Arcellx, Tubulis, and Ouro Medicines, recording billions in acquired IPR&D expenses.
$7B
Arcellx acquisition acquired IPR&D expense
Gilead records $1.75 billion IPR&D impairment following discontinuation of Phase 3 EVOKE-03 study
Gilead recognized an impairment charge of $1.75 billion for the NSCLC IPR&D intangible asset after discontinuing its Phase 3 EVOKE-03 study evaluating Trodelvy.
$1.8B
impairment charge of NSCLC IPR&D intangible asset
Gilead received FDA approval for Bixlenvo and Hepcludex, plus expanded Trodelvy indications
Gilead received FDA approval for Bixlenvo for HIV and accelerated approval for Hepcludex for chronic HDV in the U.S., along with new approvals for Trodelvy in mTNBC.
Veklury product sales plunge 69% in Q3 2026 due to lower hospitalization rates
Veklury sales fell 69% to $86 million in Q3 2026 compared to $277 million in Q3 2025, driven by lower rates of COVID-19-related hospitalizations.
$86M
Veklury product sales for the three months ended September 30, 2026
-69%
decrease in Veklury sales for the three months ended September 30, 2026
Gilead deploys multi-year enterprise resource planning (ERP) system rollout across organization
Gilead disclosed an ongoing deployment of an enterprise resource planning system and related systems scheduled in phases over the next few years.
enterprise resource planning systemERP
Gilead announced definitive agreement to acquire oral IL-23R program from PepStar Therapeutics
Gilead entered into an agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited.
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 6 signals
Gilead recognized an impairment charge of $1.75 billion in the second quarter of 2026 related to its NSCLC IPR&D intangible asset from Immunomedics after discontinuing the Phase 3 EVOKE-03 study of Trodelvy.
$1.8B
impairment charge of NSCLC IPR&D intangible asset from Immunomedics
Completed acquisitions of Arcellx, Tubulis, and Ouro Medicines incurring $11.2 billion IPR&D
Gilead completed acquisitions of Arcellx ($7.0 billion), Tubulis ($3.1 billion), and Ouro Medicines ($1.0 billion net) in the second quarter of 2026.
$11.2B
acquired IPR&D expenses for Arcellx, Tubulis, and Ouro Medicines acquisitions
antibody-drug conjugateADCCAR T-cell
FDA grants full approval for Tecartus in R/R mantle cell lymphoma
Gilead received FDA full approval for Tecartus in adult patients with relapsed or refractory mantle cell lymphoma, converting an accelerated approval from July 2020.
CAR T-cell
Gilead reported an ongoing phased deployment of an enterprise resource planning system and related systems scheduled over the next few years, requiring modifications to internal control over financial reporting.
enterprise resource planning systemERP
Earlier 10-Q filings
- 10-Q · Quarter ended Mar 31, 2026Filed · 4 signalsSEC EDGAR
Showing 10 of 16 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Gilead earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| CMS Maximum Fair Price sets $1.5B revenue headwind for 2028CMS selected Biktarvy for the Maximum Fair Price determination process, establishing a price of $2,600 per 30-day supply (a 38% discount from Medicare list price). Management expects this to create a net revenue decline of approximately $1.5 billion in 2028 across Medicare, Medicaid, 340B, and commercial spillover channels. | |
| Product sales rise 13% to $8.3B, base up 16%Third quarter total product sales rose 13% year-over-year to $8.3 billion, driven by strong performance across HIV treatment and prevention, Trodelvy, and Livdelzi. Excluding Veklury, base product sales reached $8.2 billion, up 16% year-over-year, marking the company's highest base growth rate since 2015. Demonstrates massive operational cash generation and expanding commercial budget capacity... | |
| Cell Therapy sales fall 18% due to competitive headwindsThird-quarter Cell Therapy revenue dropped 18% year-over-year to $355 million due to intensifying competitive pressure in the CAR-T space. The company is seeking to offset this decline by launching anito-cel in multiple myeloma, with an upcoming PDUFA date on December 23. | |
| Preactivation of 80% Authorized Treatment Centers for anito-cel launchAhead of anito-cel's December 23 PDUFA date in multiple myeloma, Kite is initiating preactivation programs targeting 80% of Authorized Treatment Centers within 6 months. Commercial and access teams are also targeting 90% payer coverage within 12 months to drive brand leadership within 18 months of approval. | |
| Partnership with Lakefront advances bispecific T-cell engager therapiesGilead is advancing an early-stage portfolio of bispecific T-cell engagers acquired through Ouro Medicines in partnership with Lakefront. The lead candidate, gamgertamig (BCMAxCD3), demonstrated robust activity in Phase I trials across autoimmune conditions and is on track for Phase III trials next year. | |
| Clinical hold on oral 3107 due to unexpected metabolitesGilead's once-monthly oral HIV prodrug compound GS-3107 was placed on a clinical hold after unexpected metabolite impacts were detected. Management is currently resolving the hold while simultaneously progressing backup research molecules for monthly oral treatment. |
Signal API · MCP
Track Gilead with the Signal API
One POST /v1/companies/enrich call with gilead.com returns Gilead 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"gilead.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Gilead 10-Q
When did Gilead file its latest 10-Q?
What did Gilead disclose in its latest 10-Q?
What did Gilead say on its recent earnings calls?
Where can I read Gilead's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .